{"id":"gsk2340269a","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Pneumonia"},{"rate":null,"effect":"Transaminitis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PI3K-delta is a lipid kinase predominantly expressed in leukocytes that plays a critical role in B and T cell activation and proliferation. By selectively inhibiting PI3K-delta, GSK2340269A suppresses aberrant lymphocyte activation and proliferation, reducing pathogenic immune responses. This mechanism is particularly relevant in B-cell malignancies and certain autoimmune conditions where PI3K-delta signaling drives disease pathology.","oneSentence":"GSK2340269A is a selective inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) that reduces proliferation and survival of B cells and T cells in lymphoid tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:39.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT00968539","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":130},{"nctId":"NCT00989287","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-07","conditions":"Influenza","enrollment":131},{"nctId":"NCT00951041","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-11","conditions":"Influenza","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK2340269A","genericName":"GSK2340269A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2340269A is a selective inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) that reduces proliferation and survival of B cells and T cells in lymphoid tissues. Used for Chronic lymphocytic leukemia (CLL), Follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}